中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 37 Issue 11
Nov.  2021
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2021  >  37(11): 2575-2583

Value of albumin-bilirubin grade in predicting liver function changes and prognosis of hepatocellular carcinoma patients undergoing transarterial chemoembolization: A Meta-analysis

DOI: 10.3969/j.issn.1001-5256.2021.11.018
  • 1.

    Graduate School, North China University of Science and Technology, Tangshan, Hebei 063210, China

  • 2.

    Department of Hepatobiliary Surgery, Hebei General Hospital, Shijiazhuang 050051, China

  • Received Date: 2021-03-29
  • Accepted Date: 2021-04-20
  • Published Date: 2021-11-20
    Abstract
  •   Objective  To investigate the value of albumin-bilirubin (ALBI) grade in evaluating liver function changes and prognosis of hepatocellular carcinoma (HCC) patients undergoing transarterial chemoembolization (TACE).  Methods  PubMed, the Cochrane Library, EMbase, Web of Science, OVID, CNKI, Wanfang Data, VIP, and CBM databases were searched for studies on ALBI grade for evaluating liver function changes and prognosis of HCC patients undergoing TACE published up to December 2020. After quality assessment and data extraction, RevMan 5.3 was used to perform a meta-analysis of the studies included. The chi-square test was used to evaluate heterogeneity between studies; hazard ratio (HR)/odds ratio (OR) and corresponding 95% confidence interval (CI) were used to evaluate outcome measures; funnel plots were used to assess publication bias.  Results  A total of 18 articles were included, with 9940 patients in total. The meta-analysis showed that the HCC patients with higher ALBI grades after TACE had a shorter overall survival time than those with lower ALBI grades (2nd vs 1st: HR=1.48, 95%CI: 1.39-1.57, P < 0.000 01; 3rd vs 1st: HR=2.45, 95%CI: 1.92-3.13, P < 0.000 01; 3rd vs 2nd: HR=1.91, 95%CI: 1.71-2.13, P < 0.000 01). The degree of deterioration of ALBI caused by 2 times of TACE was higher than that caused by 1 time of TACE (OR=1.91, 95%CI: 1.27-2.88, P < 0.05); the degree of deterioration of ALBI caused by 3 times of TACE was higher than that caused by 1 time of TACE (OR=3.21, 95%CI: 1.95-5.28, P < 0.05); the degree of deterioration of ALBI caused by 3 times of TACE was higher than that caused by 2 times of TACE (OR=1.70, 95%CI: 1.07-2.70, P < 0.05). In addition, ALBI grade could predict the onset of acute-on-chronic liver failure (ACLF) after TACE (OR=4.57, 95%CI: 2.76-7.57, P < 0.000 01).  Conclusion  Repeated TACE treatment can cause continuous deterioration of liver function based on ALBI, and ALBI has an important clinical value in predicting prognosis and the risk of ACLF after TACE.

     

    • FullText(HTML)
  • loading
    • References(52)
  • [1]
    BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. DOI: 10.3322/caac.21492.
    [2]
    FERLAY J, SOERJOMATARAM I, DIKSHIT R, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer, 2015, 136(5): E359-386. DOI: 10.1002/ijc.29210.
    [3]
    FORNER A, REIG M, BRUIX J. Hepatocellular carcinoma[J]. Lancet, 2018, 391(10127): 1301-1314. DOI: 10.1016/S0140-6736(18)30010-2.
    [4]
    XU D, YUAN WD. Clinical efficacy of hepatic artery chemoembolization in the treatment of patients with primary liver cancer[J]. J Prac Hepatol, 2015, 18(2): 195-196. DOI: 10.3969/j.issn.1672-5069.2015.02.024.

    胥栋, 袁伟东. 肝动脉插管化疗栓塞术治疗原发性肝癌临床疗效分析[J]. 实用肝脏病杂志, 2015, 18(2): 195-196. DOI: 10.3969/j.issn.1672-5069.2015.02.024.
    [5]
    Bureau of Medical Administration, National Health Commission of the People's Republic of China. Guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition)[J]. J Clin Hepatol, 2020, 36(2): 277-292. DOI: 10.3969/j.issn.1001-5256.2020.02.007.

    中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 临床肝胆病杂志, 2020, 36(2): 277-292. DOI: 10.3969/j.issn.1001-5256.2020.02.007.
    [6]
    LLOVET JM, BRÚ C, BRUIX J. Prognosis of hepatocellular carcinoma: The BCLC staging classification[J]. Semin Liver Dis, 1999, 19(3): 329-338. DOI: 10.1055/s-2007-1007122.
    [7]
    WIESNER R, EDWARDS E, FREEMAN R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers[J]. Gastroenterology, 2003, 124(1): 91-96. DOI: 10.1053/gast.2003.50016.
    [8]
    JOHNSON PJ, BERHANE S, KAGEBAYASHI C, et al. Assessment of liver function in patients with hepatocellular carcinoma: A new evidence-based approach-the ALBI grade[J]. J Clin Oncol, 2015, 33(6): 550-558. DOI: 10.1200/JCO.2014.57.9151.
    [9]
    XU Q, YAN Y, GU S, et al. A Novel inflammation-based prognostic score: The fibrinogen/albumin ratio predicts prognoses of patients after curative resection for hepatocellular carcinoma[J]. J Immunol Res, 2018, 2018: 4925498. DOI: 10.1155/2018/4925498.
    [10]
    GKIKA E, BETTINGER D, KRAFFT L, et al. The role of albumin-bilirubin grade and inflammation-based index in patients with hepatocellular carcinoma treated with stereotactic body radiotherapy[J]. Strahlenther Onkol, 2018, 194(5): 403-413. DOI: 10.1007/s00066-017-1256-0.
    [11]
    SAMAWI HH, SIM HW, CHAN KK, et al. Prognosis of patients with hepatocellular carcinoma treated with sorafenib: A comparison of five models in a large Canadian database[J]. Cancer Med, 2018, 7(7): 2816-2825. DOI: 10.1002/cam4.1493.
    [12]
    HAYDEN JA, CĈTÉ P, BOMBARDIER C. Evaluation of the quality of prognosis studies in systematic reviews[J]. Ann Intern Med, 2006, 144(6): 427-437. DOI: 10.7326/0003-4819-144-6-200603210-00010.
    [13]
    HO SY, LIU PH, HSU CY, et al. Prognostic role of noninvasive liver reserve markers in patients with hepatocellular carcinoma undergoing transarterial chemoembolization[J]. PLoS One, 2017, 12(7): e0180408. DOI: 10.1371/journal.pone.0180408.
    [14]
    WAKED I, BERHANE S, TOYODA H, et al. Transarterial chemo-embolisation of hepatocellular carcinoma: Impact of liver function and vascular invasion[J]. Br J Cancer, 2017, 116(4): 448-454. DOI: 10.1038/bjc.2016.423.
    [15]
    ZHAO S, ZHANG T, LI H, et al. Comparison of albumin-bilirubin grade versus Child-Pugh score in predicting the outcome of transarterial chemoembolization for hepatocellular carcinoma using time-dependent ROC[J]. Ann Transl Med, 2020, 8(8): 538. DOI: 10.21037/atm.2020.02.124.
    [16]
    KIM JH, SINN DH, LEE JH, et al. Novel albumin-bilirubin grade-based risk prediction model for patients with hepatocellular carcinoma undergoing chemoembolization[J]. Dig Dis Sci, 2018, 63(4): 1062-1071. DOI: 10.1007/s10620-018-4934-6.
    [17]
    NA SK, YIM SY, SUH SJ, et al. ALBI versus Child-Pugh grading systems for liver function in patients with hepatocellular carcinoma[J]. J Surg Oncol, 2018, 117(5): 912-921. DOI: 10.1002/jso.24992.
    [18]
    ZHONG BY, NI CF, JI JS, et al. Nomogram and artificial neural network for prognostic performance on the albumin-bilirubin grade for hepatocellular carcinoma undergoing transarterial chemoembolization[J]. J Vasc Interv Radiol, 2019, 30(3): 330-338. DOI: 10.1016/j.jvir.2018.08.026.
    [19]
    CARLING U, RØSOK B, LINE PD, et al. ALBI and P-ALBI grade in Child-Pugh A patients treated with drug eluting embolic chemoembolization for hepatocellular carcinoma[J]. Acta Radiol, 2019, 60(6): 702-709. DOI: 10.1177/0284185118799519.
    [20]
    WANG ZX, WANG EX, XIA DD, et al. Value of Child-Pugh score versus albumin-bilirubin grade in predicting the prognosis of unresectable hepatocellular carcinoma treated by transarterial chemoembolization[J]. J Clin Hepatol, 2020, 36(1): 113-117. DOI: 10.3969/j.issn.1001-5256.2020.01.025.

    王哲轩, 王恩鑫, 夏冬东, 等. Child-Pugh评分和ALBI分级预测经肝动脉化疗栓塞治疗不可切除肝细胞癌预后的价值比较[J]. 临床肝胆病杂志, 2020, 36(1): 113-117. DOI: 10.3969/j.issn.1001-5256.2020.01.025.
    [21]
    LIU F, ZHOU YF. Child-Pugh score and albumin-bilirubin classification in prognostic value of patients with hepatocellular carcinoma undergoing arterial chemoembolization[J]. Sma Healt, 2020, 6(11): 135-136. DOI: 10.19335/j.cnki.2096-1219.2020.11.052.

    刘芳, 周英发. Child-Pugh评分和白蛋白-胆红素分级在肝细胞癌经动脉化疗栓塞患者中预后的价值[J]. 智慧健康, 2020, 6(11): 135-136. DOI: 10.19335/j.cnki.2096-1219.2020.11.052.
    [22]
    HUANG H, ZHU Y, BAO ZJ. Prognostic factors of elderly patients with hepatocellular carcinoma undergoing transcatheter arte-rial chemoembolization[J]. Prac Geri, 2019, 33(6): 577-581. DOI: 10.3969/j.issn.1003-9198.2019.06.015.

    黄海, 竺越, 保志军. 肝动脉化疗栓塞术治疗老年肝癌病人的疗效及预后影响因素分析[J]. 实用老年医学, 2019, 33(6): 577-581. DOI: 10.3969/j.issn.1003-9198.2019.06.015.
    [23]
    ZHANG ZY, ZHANG GL, WAN L, et al. Prognostic value of ALBI grading in patients with hepatocellular carcinoma treated with repeated TACE[J]. Tumor, 2019, 39(9): 722-729. DOI: 10.3781/j.issn.1000-7431.2019.33.203.

    张争运, 张国梁, 万霖, 等. ALBI分级对反复行TACE治疗肝细胞癌患者预后评估的价值[J]. 肿瘤, 2019, 39(9): 722-729. DOI: 10.3781/j.issn.1000-7431.2019.33.203.
    [24]
    LEE SK, SONG MJ, KIM SH, et al. Comparing various scoring system for predicting overall survival according to treatment modalities in hepatocellular carcinoma focused on Platelet-albumin-bilirubin (PALBI) and albumin-bilirubin (ALBI) grade: A nationwide cohort study[J]. PLoS One, 2019, 14(5): e0216173. DOI: 10.1371/journal.pone.0216173.
    [25]
    HANSMANN J, EVERS MJ, BUI JT, et al. Albumin-bilirubin and platelet-albumin-bilirubin grades accurately predict overall survival in high-risk patients undergoing conventional transarterial chemoembolization for hepatocellular carcinoma[J]. J Vasc Interv Radiol, 2017, 28(9): 1224-1231. e2. DOI: 10.1016/j.jvir.2017.05.020.
    [26]
    HIRAOKA A, KUMADA T, KUDO M, et al. Hepatic function during repeated TACE procedures and prognosis after introducing sorafenib in patients with unresectable hepatocellular carcinoma: Multicenter analysis[J]. Dig Dis, 2017, 35(6): 602-610. DOI: 10.1159/000480256.
    [27]
    SAITO N, TANAKA T, NISHIOHUKU H, et al. Transarterial- chemoembolization remains an effective therapy for intermediate-stage hepatocellular carcinoma with preserved liver function[J]. Hepatol Res, 2020, 50(10): 1176-1185. DOI: 10.1111/hepr.13550.
    [28]
    WEI TF, HE SC, ZHU HD, et al. The impact of different intervals between two TACE procedures on the short-term liver functions in patients with hepatocellular carcinoma[J]. J Interv Radiol, 2020, 29(11): 1126-1130. DOI: 10.3969/j.issn.1008-794X.2020.11.014.

    魏庭丰, 何仕诚, 朱海东, 等. 原发性肝癌肝动脉化疗栓塞治疗间隔长短对近期肝功能影响的比较[J]. 介入放射学杂志, 2020, 29(11): 1126-1130. DOI: 10.3969/j.issn.1008-794X. 2020.11.014.
    [29]
    XIE XK, WANG ZY, CHEN XX, et al. Value of four scoring systems in predicting liver failure after transcatheter arterial che-moembolization in patients with hepatocellular carcinoma[J]. Chin J Clin Oncol, 2020, 47(12): 614-620. DOI: 10.3969/j.issn.1000-8179. 2020.12.347.

    谢雪焜, 王宗玉, 陈欣欣, 等. 4种评分系统预测肝细胞癌患者经肝动脉化疗栓塞术后肝衰竭的价值[J]. 中国肿瘤临床, 2020, 47(12): 614-620. DOI: 10.3969/j.issn.1000-8179.2020.12.347.
    [30]
    MOHAMMED M, KHALAF MH, LIANG T, et al. Albumin-bilirubin score: An accurate predictor of hepatic decompensation in high-risk patients undergoing transarterial chemoembolization for hepatocellular carcinoma[J]. J Vasc Interv Radiol, 2018, 29(11): 1527-1534. e1. DOI: 10.1016/j.jvir.2018.06.016.
    [31]
    de LOPE CR, TREMOSINI S, FORNER A, et al. Management of HCC[J]. J Hepatol, 2012, 56(Suppl 1): s75-s87. DOI: 10.1016/S0168-8278(12)60009-9.
    [32]
    BRUIX J, SHERMAN M. Management of hepatocellular carcinoma: An update[J]. Hepatology, 2011, 53(3): 1020-1022. DOI: 10.1002/hep.24199.
    [33]
    CHILD CG, TURCOTTE JG. Surgery and portal hypertension[J]. Major Probl Clin Surg, 1964, 1: 1-85.
    [34]
    PUGH RN, MURRAY-LYON IM, DAWSON JL, et al. Transection of the oesophagus for bleeding oesophageal varices[J]. Br J Surg, 1973, 60(8): 646-649. DOI: 10.1002/bjs.1800600817.
    [35]
    JOHNSON PJ, WILLIAMS R. Cirrhosis and the aetiology of hepatocellular carcinoma[J]. J Hepatol, 1987, 4(1): 140-147. DOI: 10.1016/s0168-8278(87)80021-1.
    [36]
    DURAND F, VALLA D. Assessment of prognosis of cirrhosis[J]. Semin Liver Dis, 2008, 28(1): 110-122. DOI: 10.1055/s-2008-1040325.
    [37]
    BAǦIRSAKÇI E, ŞAHIN E, ATABEY N, et al. Role of albumin in growth inhibition in hepatocellular carcinoma[J]. Oncology, 2017, 93(2): 136-142. DOI: 10.1159/000471807.
    [38]
    CHAN AW, CHONG CC, MO FK, et al. Incorporating albumin-bilirubin grade into the cancer of the liver Italian program system for hepatocellular carcinoma[J]. J Gastroenterol Hepatol, 2017, 32(1): 221-228. DOI: 10.1111/jgh.13457.
    [39]
    CHAN AW, CHONG CC, MO FK, et al. Applicability of albumin-bilirubin-based Japan integrated staging score in hepatitis B-associated hepatocellular carcinoma[J]. J Gastroenterol Hepatol, 2016, 31(10): 1766-1772. DOI: 10.1111/jgh.13339.
    [40]
    CHAN AW, KUMADA T, TOYODA H, et al. Integration of albumin-bilirubin (ALBI) score into Barcelona Clinic Liver Cancer (BCLC) system for hepatocellular carcinoma[J]. J Gastroenterol Hepatol, 2016, 31(7): 1300-1306. DOI: 10.1111/jgh.13291.
    [41]
    SHAO YY, LIU TH, LEE YH, et al. Modified CLIP with objective liver reserve assessment retains prognosis prediction for patients with advanced hepatocellular carcinoma[J]. J Gastroenterol Hepatol, 2016, 31(7): 1336-1341. DOI: 10.1111/jgh.13312.
    [42]
    LAU WY, LAI ECH. Loco-regional intervention for hepatocellular carcinoma[J]. J Intervent Med, 2019, 2(2): 43-46. DOI: 10.1016/jJimed.2019.07.001.
    [43]
    WANG JC, LAO XM. Research progress on HBV DNA and liver function changes after TACE of HBV-induced hepatocellular carcinoma[J]. New Chin Med, 2016, 47(5): 290-294. DOI: 10.3969/j.issn.0253-9802.2016.05.003.

    王骏成, 劳向明. HBV相关肝癌TACE术后HBV-DNA及肝功能变化的研究进展[J]. 新医学, 2016, 47(5): 290-294. DOI: 10.3969/j.issn.0253-9802.2016.05.003.
    [44]
    LENCIONI R, de BAERE T, SOULEN MC, et al. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data[J]. Hepatology, 2016, 64(1): 106-116. DOI: 10.1002/hep.28453.
    [45]
    ZHANG CJ, HE SC, TENG GJ, et al. Analysis of related factors affecting liver function for hepatocellular carcinoma after transcatheter arterial chemoembolization[J]. J Southe Univ (Med Sci Edi), 2013, 32(1): 18-22. DOI: 10.3969/j.issn.1671-6264.2013.01.005.

    张成佳, 何仕诚, 滕皋军, 等. TACE治疗原发性肝癌对肝功能影响的相关因素分析[J]. 东南大学学报(医学版), 2013, 32(1): 18-22. DOI: 10.3969/j.issn.1671-6264.2013.01.005.
    [46]
    ARIZUMI T, MINAMI T, CHISHINA H, et al. Time to transcatheter arterial chemoembolization refractoriness in patients with hepatocellular carcinoma in Kinki Criteria Stages B1 and B2[J]. Dig Dis, 2017, 35(6): 589-597. DOI: 10.1159/000480208.
    [47]
    PECK-RADOSAVLJEVIC M, RAOUL JL, LEE HC, et al. OPTIMIS: An international observational study to assess the use of sorafenib after transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC) [J]. J Clin Oncol, 2014, 32(15): TPS4155. DOI: 10.1200/jco.2014.32.15_suppl.tps4155.
    [48]
    Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Guideline for diagnosis and treatment of liver failure(2018)[J]. J Clin Hepatol, 2019, 35(1): 38-44. DOI: 10.3969/j.issn.1001-5256.2019.01.007.

    中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2018年版)[J]. 临床肝胆病杂志, 2019, 35(1): 38-44. DOI: 10.3969/j.issn.1001-5256.2019.01.007.
    [49]
    HERNAEZ R, SOLÀ E, MOREAU R, et al. Acute-on-chronic liver failure: An update[J]. Gut, 2017, 66(3): 541-553. DOI: 10.1136/gutjnl-2016-312670.
    [50]
    HSIN IF, HSU CY, HUANG HC, et al. Liver failure after transarterial chemoembolization for patients with hepatocellular carcinoma and ascites: Incidence, risk factors, and prognostic prediction[J]. J Clin Gastroenterol, 2011, 45(6): 556-562. DOI: 10.1097/MCG.0b013e318210ff17.
    [51]
    CHAN AW, CHAN RC, WONG GL, et al. New simple prognostic score for primary biliary cirrhosis: Albumin-bilirubin score[J]. J Gastroenterol Hepatol, 2015, 30(9): 1391-1396. DOI: 10.1111/jgh.12938.
    [52]
    LIU PH, HSU CY, HSIA CY, et al. ALBI and PALBI grade predict survival for HCC across treatment modalities and BCLC stages in the MELD Era[J]. J Gastroenterol Hepatol, 2017, 32(4): 879-886. DOI: 10.1111/jgh.13608.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(9)  / Tables(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (1255) PDF downloads(60) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return